AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio total assets
Total assets on the balance sheet at the end of each period.
AnaptysBio's total assets was $316.98M at Jun 30, 2026. For fiscal 2025 it was $364.40M, down 24.7% from the year before. The highest annual figure on record is $643.07M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.40M | -24.7% |
| FY2024 | Dec 31, 2024 | $483.83M | +7.0% |
| FY2023 | Dec 31, 2023 | $452.39M | -25.9% |
| FY2022 | Dec 31, 2022 | $610.38M | -5.1% |
| FY2021 | Dec 31, 2021 | $643.07M | +54.4% |
| FY2020 | Dec 31, 2020 | $416.55M | -4.3% |
| FY2019 | Dec 31, 2019 | $435.20M | -14.5% |
| FY2018 | Dec 31, 2018 | $509.00M | +54.5% |
| FY2017 | Dec 31, 2017 | $329.36M | +429.7% |
| FY2016 | Dec 31, 2016 | $62.18M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $316.98M | -5.4% |
| Q1 FY2026 | Mar 31, 2026 | $329.68M | -21.9% |
| Q4 FY2025 | Dec 31, 2025 | $364.40M | -24.7% |
| Q3 FY2025 | Sep 30, 2025 | $353.10M | -28.4% |
| Q2 FY2025 | Jun 30, 2025 | $335.25M | -21.6% |
| Q1 FY2025 | Mar 31, 2025 | $422.05M | +4.0% |
| Q4 FY2024 | Dec 31, 2024 | $483.83M | +7.0% |
| Q3 FY2024 | Sep 30, 2024 | $493.42M | +1.3% |
| Q2 FY2024 | Jun 30, 2024 | $427.38M | -17.4% |
| Q1 FY2024 | Mar 31, 2024 | $405.84M | -26.5% |
| Q4 FY2023 | Dec 31, 2023 | $452.39M | -25.9% |
| Q3 FY2023 | Sep 30, 2023 | $487.33M | -21.2% |
| Q2 FY2023 | Jun 30, 2023 | $517.10M | -14.4% |
| Q1 FY2023 | Mar 31, 2023 | $551.79M | -11.7% |
| Q4 FY2022 | Dec 31, 2022 | $610.38M | -5.1% |
| Q3 FY2022 | Sep 30, 2022 | $618.50M | +45.8% |
| Q2 FY2022 | Jun 30, 2022 | $603.85M | +41.6% |
| Q1 FY2022 | Mar 31, 2022 | $625.17M | +57.7% |
| Q4 FY2021 | Dec 31, 2021 | $643.07M | +54.4% |
| Q3 FY2021 | Sep 30, 2021 | $424.34M | +10.3% |
| Q2 FY2021 | Jun 30, 2021 | $426.57M | +6.2% |
| Q1 FY2021 | Mar 31, 2021 | $396.42M | -6.6% |
| Q4 FY2020 | Dec 31, 2020 | $416.55M | -4.3% |
| Q3 FY2020 | Sep 30, 2020 | $384.75M | -14.8% |
| Q2 FY2020 | Jun 30, 2020 | $401.75M | -16.3% |
| Q1 FY2020 | Mar 31, 2020 | $424.23M | -14.2% |
| Q4 FY2019 | Dec 31, 2019 | $435.20M | -14.5% |
| Q3 FY2019 | Sep 30, 2019 | $451.51M | -13.7% |
| Q2 FY2019 | Jun 30, 2019 | $480.15M | +56.9% |
| Q1 FY2019 | Mar 31, 2019 | $494.23M | +57.0% |
| Q4 FY2018 | Dec 31, 2018 | $509.00M | +54.5% |
| Q3 FY2018 | Sep 30, 2018 | $523.12M | +329.0% |
| Q2 FY2018 | Jun 30, 2018 | $306.02M | +134.7% |
| Q1 FY2018 | Mar 31, 2018 | $314.84M | +140.1% |
| Q4 FY2017 | Dec 31, 2017 | $329.36M | +429.7% |
| Q3 FY2017 | Sep 30, 2017 | $121.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $130.41M | – |
| Q1 FY2017 | Mar 31, 2017 | $131.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $62.18M | – |
See a number that looks wrong?